



Idera to Present at the Jefferies 2017 Healthcare Conference

June 5, 2017 3:01 PM EDT

CAMBRIDGE, Mass. and EXTON, Pa., June 05, 2017 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that Idera's Chief Executive Officer, Vincent Milano will provide a corporate overview and update at the Jefferies 2017 Healthcare Conference on Thursday, June 8, 2017 at 11:00 a.m. Eastern Time at the Grand Hyatt Hotel in New York City.

Live audio webcast of Idera's presentations will be accessible in the Investors and Media section of Idera's website at <http://www.iderapharma.com>. Archived versions will also be available on the Company's website after the event for 90 days.

About Idera Pharmaceuticals

Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Idera's proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. In addition to its TLR programs, Idera has created a third generation antisense technology platform using its proprietary technology to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.

Investor and Media Contact

Robert Doody

VP, IR & Corporate Communications

617-679-5515 (office)

484-639-7235 (mobile)

rdooddy@iderapharma.com



Idera Pharmaceuticals, Inc.